國際新聞精選周三（2017年4月5日）

2017年4月5日 | Filed under: | Posted by: 編輯 D

BMS’ Opdivo shown to improve five-year lung cancer survival

Bristol-Myers Squibb has unveiled “unprecedented” long-term survival data for its cancer immunotherapy Opdivo, showing that nearly one in six patients with previously-treated, advanced non-small cell lung cancer (NSCLC) were still alive at five years.

In the Phase Ib single arm trial, which primarily looked at safety and tolerability across different doses, 16 percent of 129 patients reached the five-year survival mark when, typically, the five-year survival rate for advanced lung cancer is just 1 percent.【閱讀全文】

Teva’s Austedo wins US nod for Huntington’s patients

US regulators have green-lighted Teva Pharmaceutical Industries’ Austedo for the treatment of chorea associated with Huntington’s disease (HD), offering patients the first new treatment option in nearly a decade.

A rare and fatal neurodegenerative disorder, HD affects more than 35,000 people in the US. Chorea - involuntary, random and sudden, twisting and/or writhing movements - is a key physical manifestation of this disease occurring in around 90 percent of patients.【閱讀全文】

Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary

NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported interim results from NLG2103, a Phase 2 study evaluating its IDO pathway inhibitor, indoximod, in combination with checkpoint inhibitors for the treatment of patients with advanced melanoma.【閱讀全文】

AACR – Newlink slipstreams behind Incyte

After Incyte moved into immuno-oncology’s fast track and had analysts hailing the IDO pathway as the next big thing, data unveiled today at the AACR meeting suggested that Newlink Genetics was at least going to try to give its rival a run for its money.【閱讀全文】

CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR

CBT Pharmaceuticals, Inc. (CBT), a life sciences company focused on developing innovative oncology therapeutics, presented preclinical data on CBT-101 (bozitinib, PLB-1001, CBI-3103), a highly specific small molecule inhibitor of c-MET receptor tyrosine kinase, demonstrating its selectivity, safety, and efficacy in suppressing tumor growth in lung, gastric, hepatic and pancreatic human primary tumor models. The data were presented in a poster at the American Association for Cancer Research Annual Meeting (AACR) being held from April 1 – 5, 2017 in Washington, D.C.【閱讀全文】

Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs

Onconova Therapeutics Inc. ONTX, +6.98% stock surged as much as 18% in premarket trade Tuesday after the company said its two cancer drugs had positive pre-clinical results. Onconova shares were valued at $3.01 as of Monday's close. One drug, ON 123300, was found in a model to work as well as Pfizer Inc.'s PFE, +0.29% Ibrance, and could lead to less infection susceptibility, the company said. The other drug, ON 150030, showed promising results in relapsed and refractory Acute Myeloid Leukemia, the company said. Both results were presented on Monday at the American Association for Cancer Research's annual meeting. Onconova shares have surged 30.3% over the last three months, compared with a 3.9% rise in the S&P 500 SPX, +0.06%【閱讀全文】

Paratek shares surge after antibiotic phase 3 hits endpoints

Shares in Paratek Pharmaceuticals jumped 35% in premarket trading on the back of data from a phase 3 trial of its antibiotic candidate omadacycline. The clinical trial met its primary endpoint of noninferiority to moxifloxacin, teeing Paratek up to file for FDA approval in the first quarter of next year.【閱讀全文】

Amgen Offers A Money-Back Guarantee For Its Cholesterol Drug Repatha

The high cost of drugs continues to dominate the news in the biopharmaceutical industry. Recent data for new cancer drugs that upregulate the immune system to fight melanoma, lung cancer, etc. are very promising. Yet, stories on these wonder drugs quickly dive into their costs–justifiably so. For example, Bristol-Myers Squibb’s combination of Opdivo and Yervoy can cost up to $21,000–a month! But new cancer therapies are not unique with respect to pricing. Similar stories can be found with drugs to treat rare diseases, hepatitis C, multiple sclerosis, etc.【閱讀全文】

美中藥源原創文章，轉載注明出處并添加超鏈接，商業用途需經書面授權。
★更多深度解析訪問《美中藥源》~

★ 請關注《美中藥源》微信公眾號 ★